Heme/Onco Flashcards
1
Q
CD 34+
A
hematopoietic stem cell
2
Q
membrane contains Cl-/HCO3- antiporter
A
RBC
3
Q
don;t produce net ATP during glycolysis
A
RBC
4
Q
2,3, BPG in RBC
A
produced from 1,3 BPG by bisphosphoglycerate mutase using ATP
5
Q
platelet contents
A
dense granules (ADP, Ca2+), alpha granules (vWF, fibrinogen)
6
Q
where is 1/3 of platelets stored
A
spleen
7
Q
blood cell differentiation fro highest to lowest
A
neutrophils, lymphocytes, monocytes, eosinophils, basophils
8
Q
hypersegmented polys
A
B12/folate deficiency
9
Q
high cortisol state and neutrophils
A
disrupts ability of neutrophils to adhere to wall of damaged tissue releasing them into circulation
10
Q
frosted glass cytoplasm
A
monocytes
11
Q
what activates macrophages
A
gamma interferon
12
Q
surfacemarker for macrophages
A
CD 14
13
Q
eosinophils produce
A
histaminase and arylsulfatase
14
Q
causes of eosinophilia
A
neoplastic, asthma, allergic, collagen vascular disease, parasites
15
Q
mediates allergic reaction
A
basophil
16
Q
contain heparin, histamine, LTD4
A
basophil
17
Q
basophilia
A
usually seen with CML
18
Q
can bind Fc portion of IgE
A
mast cell
19
Q
involved in type 1 hypersensitivity
A
mast cell
20
Q
chromolyn sodium
A
prevents mast cell degranulation
21
Q
increased production of gastric acid by parietal cells
A
systemic mastocytosis
22
Q
most sensitive cells to radiation
A
lymphocytes
23
Q
produces lymphocytosis promoting factor and blocks lymphocytes from leaving blood
A
Bordetella pertussis
24
Q
express CD8, recognize MHC I
A
cytotoxic T cells
25
express CD28
regulatory T cells
26
universal plasma donor
AB
27
Rho immune globulin
given to mother at first delivery
28
clot instability, delayed, recurrent bleeding after trauma
factor XII deficiency
29
decreased ESR
polycythemia, sickle cell anemia, CHF, microcytosis, hypofibrinogenemia
30
acanthocyte (spur cell)
liver disease, abetalipoproteinemia
31
basophilic stippling
TAL: thalassemia, anemia of chronic disease, lead poisoning
32
bite cell
G6PD deficiency
33
elliptocyte
hereditary elliptocytosis
34
macro-ovalocyte
megaloblastic anemia (also hypersegmented PMNs), marrow failure
35
ringed sideroblasts
sideroblastic anemia (excess iron in mitochondria)
36
schistocyte
DIC, TTP/HUS, traumatic hemolysis
37
spherocyte
hereditary spherocytosis, autoimmune hemolysis
38
teardrop cell
bone marrow infiltration (myelofibrosis)
39
target cell
HALT: HbC disease, asplenia, liver disease, thalassemia
40
Heinz bodies
oxidation of iron, G6PD, similar in alpha-thalassemia
41
Howell-Jolly bodies
basophilic nuclear remnant normally removed by splenic macrophages; hyposplenia or asplenia, mothball ingestion (naphthalene)
42
Plummer-Vinson syndrome
iron deficiency anemia, esophageal webs, atrophic glossitis
43
koilonychia, pica
iron deficiency anemia
44
alpha thalassemia cis deletion
Asians, worse than trans
45
alpha thalassemia trans deletion
Africans
46
4 gene deletion alpha thalassemia
Hb Barts, hydrops fetalis
47
3 gene deletion alpha thalassemia
HbH
48
which chromosome is the mutations on in alpha thalassemia
16
49
which chromosome is the mutation on in beta thalassemia
11
50
point mutations in splice sites and promoter sequences
beta thalassemia
51
prevalent in mediterranean population
beta thalassemia
52
asymptomatic, increased HbA2 on electrophoresis, target cells
beta thalassemia minor
53
severe anemia, risk for aplastic crisis with parvovirus B19, marrow expansion
beta thalassemia major
54
increased HbF
beta thalassemia major
55
inhibits ferrochelatase and ALA dehydratase
lead poisoning
56
house with chipped paint, basophilic stippling
lead poisoning
57
lead poisoning
LEADS" lead lines on gingiva, encephalopathy and erythrocyte basophilic stippling, abdominal colic, sideroblastic anemia, drops (wrist, foot), dimercaprol and EDTA for treatment, succimer for chelation in kids
58
sideroblastic anemia causes
X-linked defect in gamma-ALA synthase, alcohol, lead, isoniazid
59
sideroblastic anemia treatment
B6 (cofactor for gamma-ALA synthase)
60
anemic of chronic disease treatment
exogenous erythropoetin
61
can cause folate deficiency
methotrexate, trimethoprim, phenytoin
62
macrocytic anemia, hypersegmented neutrophils, glossitis, increased homocysteine, normal methylmalonate
folate deficiency anemia
63
macrocytic anemia, hypersegmented neutrophils, glossitis, increased homocysteine, increased methylmalonic acid
B12 deficiency anemia (converts methylmalonic acid to succinyl CoA
64
normal Schilling test
low dietary intake of B12
65
cause of B12 deficiency
Crohns, pernicious anemia, Diphyllobothrium latum, PPI
66
can't cleave off R-binder from B12
pancreatic insufficiency
67
megaloblastic anemia in a child that can't be cured with folate or B12
orotic aciduria
68
hypersegmented neutrophils, glossitis, orotic acid in urine
orotic aciduria
69
orotic aciduria treatment
uridine monophosphate
70
decreased haptoglobin, increased LDH, Hn in urine
intravascular hemolysis
71
increased LDH, increased UCB, jaundice
extravascular hemolysis
72
correct for falsely elevated reticulocytes
multiply by Hct/45
73
master regulator of iron homeostasis
hepcidin (produced in the liver); inhibits iron transport across gut mucosa
74
anemia without splenomegaly
aplastic anemia
75
pancytopenia, dry bone marrow tap, pallor, purpura, mucasal bleeding
aplastic anemia
76
aplastic anemia causes
radiation, benzene, chroramphenicol, alkylating agents, antimetabolites, parvovirus B19, EBV, HIV, HCV, fanconi's anemia (DNA repair defect)
77
thymoma
associated with pure red cell aplasia
78
complication of any hemolytic anemia
pigmented gallstones, predisposes to folic acid deficiency
79
autosomal dominant defect in spectrin, ankryrin, increased MCHC, premature removal of RBCs by spleen
hereditary spherocytosis
80
splenomegaly, aplastic crisis (B19), positive osmotic fragility test
hereditary spherocytosis
81
hereditary spherocytosis treatment
splenectomy
82
X-linked recessive decrease in glutathione
G6PD
83
hemolytic anemia following oxidant stress
G6PD
84
back pain, hemoglobinuria, Heinz bodies, bite cells, dercreased production of 6-phosphogluconate
G6PD
85
decreased ATP, hemolytic anemia in newborn
puryvate kinase deficiency
86
HbC
glutamic acid to lysine mutation at residue 6 in beta globin
87
complement-mediated RBC lysis, absent GPI
paroxysmal nocturnal hemoglobinuria
88
hemolytic anemia, pancytopenia, venous thrombosis
paroxysmal nocturnal hemoglobinuria
89
CD55/59 negative on flow cytometry
paroxysmal nocturnal hemoglobinuria
90
treatment for paroxysmal nocturnal hemoglobinuria
eculizumab
91
paroxysmal nucturnal hemoglobinuria screening
sucrose test
92
substitution of glutamic acid with valine at position 6 of beta chain
sickle cells anemia
93
low O2 in sickle cell
precipitates sickling--> deoxygenated HbS polymerizes-->promotes hydrophobic interaction among Hb molecules
94
crew cut skull on x-ray, aplastic crisis, autosplenectomy, increased risk of infection with encapsulated organisms, salmonella osteomyelitis, renal papillary necrosis
sickle cell anemia
95
sickle cell anemia treatment
hydroxyurea (increases HbF)
96
gardos channel blockers
hinder efflux of K+ and water from cells, preventing dehydration of RBCs and decrease polymerization of HbS
97
metabisulfite screen
causes cells with any amount of HbS to sickle, predisposed to develop folic acid deficiency
98
HbC
normocytic anemia with extravascular hemolysis, mutation in beta chain
99
IgG
extravascular hemolysis, spherocytes, warm agglutinin
100
IgM
intravascular hemolysis, cold agglutinin
101
warm agglutinin
SLE, CLL, alpha-methyldopa
102
cold agglutinin
acute anemia triggered by cold; CML, Mycoplasma pneuminia, mono
103
direct Coombs test
anti-Ig Ab added to pts serum
104
indirect Coombs test
normal RBCs added to pts serum
105
infectious mono
EBV infection, lymphocytic leukocytosis, reactive CD8+, generalized LAD (paracortex), splenomegaly (PALS), risk for splenic rupture
106
monospot test
detects IgM heterophile Ab; negative-->CMV cause
107
definitive diagnosis for mono
testing EBV viral capsid antigen
108
rash if exposed to penicillin
mono
109
often fatal leukemia, pigmentary skin changes, malformation of heart, kidney, and limbs
Fanconi anemia (mutation in gene that functions in BRCA)
110
BRCA
repairs damage to DNA caused by cross-linking agents
111
accumulation of protoporphyrin, gamma-ALA in blood
lead poisoning
112
defective porphobilibogen deaminase
acute intermittent porphyria
113
accumulation of porphobilinogen, gamma-ALA, uroporphyrin in urine
acute intermittent porphyria
114
acute intermittent porphyria treatment
glucose and heme (inhibit ALA synthase)
115
painful abdomen, port-wine colored urine, polyneuropathy, psychological disturbances, precipitated by drugs
acute intermittent porphyria
116
defective uroporphyrinogen decarboxylase
porphyria cutanea tarda
117
uroporphyrin in urine (tea-colored urine)
porphyria cutanea tarda
118
blistering cutaneous photosensitivity
porphyria cutane tarda
119
normal bleeding time
2-7 min
120
normal PT time
11-15 s
121
normal PTT time
25-40 s
122
factor VIII deficiency, increased PTT
hemopylia A
123
deficiency of factor IX, increased PTT
hemophylia B
124
activated by epoxide reductase in liver, generated by bacteria in gut
vitamin K
125
decreased synthesis of factors II, VII, IX, X, protein C, and protein S
vitamin K deficiency
126
decreased Gp1b, defect in adhesion, increased bleeding time
Bernard-Soulier syndrome
127
decreased GpIIb/IIIa, defect in aggregation, no platelet clumping on smear
Glanzmann's thrombasthemia
128
anti-GpIIb/IIIa Ab, increased magakaryocytes, increased bleeding time
ITP
129
deficiency of ADAMSTS 13-->decreased degradation of vWF multimers-->platelet aggregation and thrombosis, schistocytes, increased LDH and magakaryocytes
TTP
130
neurologic and renal symptoms, fever, thrombocytopenia, microangiopathic hemolytic anemia
TTP
131
liver failure effect on coagulation monitored by
PT
132
uremic platelet dysfunction
can occur in dialysis pts
133
diagnosed by ristocetin cofactor assay
von Willebrand's disease
134
von Willebrand disease treatment
desmopressin (DDAVP)-->releases vWF stored in endothelium
135
easy bleeding from mucosal surfaces, normal platelet count
von Willebrand disease
136
DIC treatment
transfuse blood products and cryoprecipitate
137
DIC causes
sepsis (gram -), trauma, OB, acute pancreatitis, malignancy, nephrotic syndrome, transfusions
138
increased fibrin split products (D dimer)
DIC
139
factor V resistant to degradation by activated protein C
factor V Leiden
140
most common cause of inherited hypercoagulability in whites
factor V Leiden
141
prothrombin gene mutation
in 3' untranslated region-->increased production of prothrombin
142
increase in PTT is blunted after heparin
antithrombin deficiency
143
decreased ability to inactivate factors V and VIII, increased risk for thrombotic skin necrosis with hemorrhage following warfarin administration
protein C or S deficiency
144
used to treat deficiencies in fibrinogen and factor VIII
cryoprecipitate
145
blood transfusion risks
hypocalcemia (citrate is Ca2+ chelator), hyperkalemia
146
protamine
heparin reversal
147
CML vs leukemoid reaction
decreased leucocyte alkaline phosphatase in CML
148
Reed-Steinberg cells, associated with EBV, colalized, contignous spread, low-grade fever, night sweats, weight loss
Hodgkin's lymphoma
149
multiple peripheral nodes, noncontiguos spread, common in 2-40 y.o., associated with HIV and immunosuppression
non-Hodgkin's lymphoma
150
CD30+and CD15+ B cell origin
Reed-Steinberg cell
151
Hodgkin's lymphoma that is most common with best prognosis
nodular sclerosing form
152
t(8,14)
Burkitt's lymphoma, c-myc(8), heavy chain Ig (14)
153
starry sky, associated with EBV, jaw lesion endemic in Africa
Burkitt lymphoma; high ki67 proliferative fraction
154
enlarging lymph node
diffuse large B cell lymphoma
155
t(11,14)
Mantle cell lymphoma, cyclin d1(11), heavy chain Ig(14)-->, poor prognosis, CD5+
156
heavy chain Ig
promotes G1/S transition
157
painless LAD in an older male
mantle cell lymphoma
158
t(14,18)
follicular lymphoma, heavy chain Ig(14), bcl-2(18)
159
bcl-2
inhibits apoptosis
160
follicular lymphoma treatment
rituximab (anti CD20)
161
adult from Japan, West Africa, or Caribbean with cutaneous lesions
adult T-cell lymphoma, caused by HTLV-1
162
adults with cutaneous patches/nodule, CD4+
mycosis fungoides/Sezary syndromeq
163
can produce erythropoietin, associated with polycythemia
cerebellar hemangioblastoma
164
associated with chronic inflammatory states
marginal zone lymphoma
165
fried egg cells that produce IgG or IgA
multiple myeloma
166
hypercalcemia, renal insufficiency, anemia, bone lytic lesions, back pain
multiple myeloma; activates RANK receptors on osteoclasts, eosinophilic casts
167
increased susceptibility to infection, primary amyloidosis, punched out lytic bone lesions on X-ray, M spike, Bence-Jones protein (Ig light chain), rouleaux
multiple myeloma
168
M spike (IgM), no lytic bone lesions, visual and neuro deficits
Waldenstrom's macroglobulinemia
169
asymptomatic precursor to multiple myeloma
MGUS
170
leukemia common in <15 y.o., increased lymphoblasts in peripheral blood smear
ALL
171
leukemia with mediastinal mass
T-cell ALL
172
TdT+, CALLA+, most responsive to therapy
ALL
173
associated with Down syndrome after 5 y.o.
ALL
174
ALL with better prognosis
t(12,21)
175
ALL with poor prognosis
t(9,22)
176
asymptomatic leukemia in adults >60 y.o., smudge cells
CLL (deletion of 13q)
177
leukemia associated with autoimmune hemolytic anemia
CLL
178
splenomegaly, pancytopenia, dry tap on boe marrow, absent lymphadenopathy, TRAP positive
hairy cell leukemia
179
hairy cell leukemia treatment
cladribine, adenosine analog (2-CDA)
180
rash, generalized LAD with HSM, lytic bone lesions
ATLL
181
leukemia common at 65, Auer rods
AML, myeloperoxidase crystalized as Auer rods; release of Auer rods can lead to DIC
182
t(15,17)
M3 subtype of AML
183
responds to all-trans retinoic acid (vitamin A)
M3 AML
184
leukemia in 30-60 y.o., increased basophils, splenomegaly
CML
185
t(9,22)
CML (bcr-abl)
186
CML treatment
imatinib
187
LAP negative granulocytes
CML
188
associated with Down syndrome before age 5
AML
189
child with erythematous papulaes, nodules, scaling plaques, lytic bone lesions
Langerhans cell histiocytosis
190
cells express S-100 and CD1a, birbeck granules
Langerhans cell histiocytosis
191
pathogenic fracture in adolescent
eosinophilic granuloma, benign
192
scalp rash, lytic skull defects, diabetes insipidus, exophthalmos in a child
Hard-Schuller-Christian disease, malignant
193
constitutively active JAK 2 receptors, proliferate without EPO stimulation
polycythemia vera
194
intense itching after hot shower
polycythemia vera
195
essential thrombocytosis
JAK 2 kinase mutation, platelet proliferation
196
JAK 2 kinase mutation, fibrotic obliteration of bone marrow, teardrop cell
myelofibrosis
197
polycythemia vera treatment
phlebotomy, hydroxyurea
198
cofactor for activation of antithrombin
heparin
199
decreases thrombin, decreases factor Xa, short half-life
heparin
200
anticoagulant used during pregnancy
heparin
201
which test to follow heparin
PTT
202
heparin antidote
protamine sulfate
203
act more on factor Xa
LMW heparin (enoxaparin, dalteparin)
204
IgG Ab against heparin bound to platelet factor 4
HIT
205
HIT treatment
argatroban (direct thrombin inhibitor)
206
treating HIT with this produces possibility of skin necrosis
coumadin
207
inhibit thrombin
lepirudin, bivalirudin
208
alternative to heparin for anticoagulating HIT
lepirudin, bivalirudin
209
interferes with normal synthesis and gamma-carboxylation of vitamin K-dependent clotting factors
warfarin
210
anticoagulant metabolized by p450
warfarin
211
test used to follow warfarin effects
PT
212
can predispose to paradoxical thrombosis in pts with congenital deficiency of protein C or S
warfarin
213
used for chronic anticoagulation
warfarin
214
warfarin overdose
fresh frozen plasma or vitamin K
215
aid in conversion of plasminogen to plasmin
thrombolytics (PAs, streptokinase, urokinase)
216
may cause reperfusion arrhythmia, bleeding, contraindicated with history of intracranial bleeding
thrombolytics
217
thrombolytics toxicity
treat with aminocaproic acid (inhibitor of fibrinolysis)
218
irreversibly inhibits COX-1 and COX-2 by covalent acetylation, no effects on PT, PTT
aspirin
219
side effects: gastric ulceration, tinnitus
aspirin
220
aspirin overdose
respiratory alkalosis, metabolic acidosis
221
alternative treatment for aspirin allergy
clopidogrel
222
ADP receptor inhibitors
clopidogrel, ticlopidine, prasugrel, ticagrelor
223
side effects of neutropenia, fever, mouth ulcers
ADP receptor inhibitors(esp. ticlopidine)
224
factor Xa inhibitors
no significant antithrombin activity, can be used for DVT; ex: fondaparinux
225
phosphodiesterase III inhibitors, increase cAMP in platelets-->inhibiting platelet aggregation
cilostazol, dipyridamole, milrinone
226
used for intermittent claudication, prevent stroke or TIA, angina prophylaxis, increased contractility
phosphodiesterase III inhibitors
227
side effects of nausea, headache, facial flushing, hypotension, abdominal pain
phosphodiesterase III inhibitors
228
GpIIb/IIIa inhibitors
abciximab, eptifibatide, tirofiban
229
made from monoclonal Ab Fab fragments
abciximab
230
used for acute coronary syndromes, percutaneous transluminal coronary angioplasty
GpIIb/IIIa inhibitors
231
side effects of bleeding, thrombocytopenia
GpIIb/IIIa inhibitors
232
inhibit fibrinolysis
aminocaproic acid, tranexamic acid
233
folic acid analog that inhibits dihydrofolate reductase, decreased dTMP-->decreased DNA and protein synthesis
methotrexate
234
used for leukemias, lymphomas, choriocarcinomas, sarcomas
methotrexate
235
used for abortion, ectopic pregnancy, RA, psoriasis
methotrexate
236
effects can be overcome by adding THF
methotrexate
237
side effect of myelosuppression
methotrexate(reversible with leucovorin: folinic acid)
238
side effects of macrovesicular fatty change in liver, mucositis, teratogenic
methotrexate
239
effect can't be overcome by adding THF
5-FU
240
pyrimidine analog bioactivated to 5F-dUMP which covalentrly complexes folic acid-->inhibits thymidylate synthase
5-FU
241
used for colon cancer, basal cell carcinoma
5-FU
242
side effects of myelosuppression not reversible with leucovorin, photosensitivity
5-FU
243
5-FU overdose
thymidine
244
pyrimidine analog used for leukemia, lymphoma
cytarabine (arabinofuranosyl cytidine)
245
side effects of leukopenia, thrombocytopenia, megaloblastic anemia
cytarabine
246
purine analogs-->decrease de novo purine synthesis
azathioprine, 6-MP, 6-TG
247
activated by HGPRT, used to treat leukemias
azathioprine, 6-MP, 6-TG
248
side effects of bone marrow, GI liver
azathioprene, 6-MP, 6-TG
249
metabolized by xanthine oxidase-->increased toxicity with allopurinol
azathioprine, 6-MP, 6-TG
250
intercalates in DNA with side effect of myelosuppression
dactinomycin (actinomycin D)
251
used to treat Wilms tumor, Ewig's sarcoma, rhabdomyosarcoma, childhood tumors
dactinomycin
252
generate free radicals, noncovalently intercalate in DNA
doxorubicin (adriamycin), daunorubicin
253
used to treat solid tumors, leukemias, lymphomas
doxorubicin (adriamycin), daunorubicin
254
side effects of dilated cardiomyopathy, myelosuppression, alopecia
doxorubicin (adriamycin), daunorubicin
255
iron chelating agent used to prevent cardiotoxicity
dexrazoxane
256
induces free radical formation which causes breaks in DNA strands
bleomycin
257
used to treat testicular cancer, Hodgkin's lymphoma
bleomycin
258
side effects of pulmonary fibrosis, skin changes, minimal myelosuppression
bleomycin
259
covalently x link DNA at guanine N-7, require bioactivation by liver
cyclophosphamide, ifosfamide
260
used for solid tumors, leukemia, lymphoma, some brain cancers
cyclophosphamide, ifosfamide
261
side effects of myelosuppression, hemirrhagic cystitis, partially prevented with mesna (thiol group binds toxic metabolite)
cyclophosphamide, ifosfamide
262
used to treat brain tumors, require bioactivation
nitrosoureas (carmustine, lomustine, semustine, streptozocin)
263
CNS toxicity
nitrosoureas (carmustine, lomustine, semustine, streptozocin)
264
alkylates DNA
busulfan
265
used to treat CML, prior to bone marrow transplant
busulfan
266
side effects of pulmonary fibrosis, hyperpigmentation
busulfan
267
tumor lysis syndrome prevention
hydration, allopurinol or rasburicase
268
cell-cycle methylating agent that requires enzymatic activation in liver
dacarbazine
269
alkaloids that bind to tubulin in M phase and block polymerization
vincristine, vinblastine
270
vincristine, vinblastine use
solid tumors, leukemias, lymphomas
271
side effects of neurotoxicity, paralytic ileus
vincristine
272
side effect of bone marrow suppression
vinblastine
273
hyperstabilize polymerized microtubules in M phase--> mitotic spindles can't break down
paclitaxel, taxols
274
used for ovarian and breast carcinomas
paclitaxel, taxols
275
paclitaxel side effects
myelosuppression, hypersensitivity
276
cross-link DNA
cisplatin, carboplatin
277
used for testicular, bladder, ovary, and lung carcinomas
cisplatin, carboplatin
278
side effects of nephrotoxicity, acoustic nerve damage
cisplatin, carboplatin
279
cisplatin, carboplatin nephrotoxicity prevention
amifostine (free radical scavenger) and chloride diuresis
280
inhibit topoisomerase II
etoposide, teniposide
281
etoposide, teniposide uses
solid tumors, leukemias, lymphomas
282
etoposide, teniposide side effects
myelosuppression, GI irritation, alopecia
283
inhibit topoisomerase I
irinotecan, topotecan
284
inhibits ribonucleotide reductase-->s phase specific
hydroxyurea
285
used to treat melanoma, CML, sickle cell
hydroxyurea
286
hydrozyurea side effects
bone marrow suppression, GI upset
287
may trigger apoptosis, may even work on non-dividing cells
prednisone, prednisolone
288
used to treat CLL, non-Hodgkin's lymphoma, immunosuppressant for autoimmune diseases
prednisone
289
side effects fo Cushing-like symptoms, immunosuppression, cataracts, acne, osteoporosis, hypertension, peptic ulcers, hyperglycemia, psychosis
prednisone
290
SERMs: receptor antagonists in breast and agonists in bone; block binding of estrogen to estrogen receptor-positive cells
tamoxifen, raloxifene
291
used in breast cancer treatment and prevention
tamoxifen, raloxifene
292
side effect of increased risk of endometrial cancer, hot flashes
tamoxifen
293
monoclonal Ab against HER-2, tyrosine kinase
trastuzumab (herceptin)
294
trastuzumab toxicity
cardiotoxicity
295
philadelphia chromosome bcr-able tyrosine kinase inhibitor
imatinib (gleevec)
296
used to treat CML, GI stromal tumors, with side effect of fluid retention
imatinib
297
monoclonal Ab against CD20
rituximab
298
used for non-Hodgkin's lymphoma, RA (With methotrexate)
rituximab
299
small molecule inhibitor of forms of B-Raf kinase with V600E mutation
vemurafenib
300
used for metastatic melanoma
vemurafenib
301
monoclonal Ab against VEGF, inhibits angiogenesis
bevacizumab
302
bevacizumab use
solid tumors
303
decreased CD16
increase in immature neutrophils
